Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Triple-Negative Breast Cancer: early-phase trial registry
3 of 6 indexed Metastatic Triple-Negative Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Metastatic Triple-Negative Breast Cancer: 6 US clinical trials tracked, 3 recruiting.
Metastatic Triple-Negative Breast Cancer is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Nippon Kayaku Co., running 1 of these trials.
Enrollment posture brief
Registry condition metastatic-triple-negative-breast-cancer
OPEN 3 | RECR 50% | LATE 0 | EARLY 6 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Metastatic Triple-Negative Breast Cancer lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Triple-Negative Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Triple-Negative Breast Cancer is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Triple-Negative Breast Cancer research.
Nippon Kayaku Co. accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Triple-Negative Breast Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 55 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.
-
Metastatic Triple-Negative Breast Cancer research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Saci Nivo Rela for TNBC
Yale University
NCT06963905
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT05570253
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
NCT07011654
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
AstraZeneca
NCT03330847
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Wake Forest University Health Sciences
NCT06027268
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
Nippon Kayaku Co.
NCT01238952
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Triple-Negative Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Triple-Negative Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Triple-Negative Breast Cancer page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Metastatic Triple-Negative Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nippon Kayaku Co. sponsors the most Metastatic Triple-Negative Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Nippon Kayaku Co.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Triple-Negative Breast Cancer condition card totals 6 registered trials; most-linked intervention NK012 and carboplatin; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.